RxDoctor Payments Data

Josephine Abraham, MD

Nephrology · Salt Lake City, UTNPI 1942260229

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Genentech, Inc.. That places this record below the midpoint for nephrology clinicians in UT, where the typical reported total is $1,171.

$52in general payments, 2019–2025

Across 1 payment — averaging $51.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$52
$566,621in research payments, 2019–2025

Across 88 payments — averaging $6438.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$290K
  • Genentech, Inc.$147K
  • E.r. Squibb & Sons, L.L.C.$82K
  • Travere Therapeutics, Inc.$34K
  • Recor Medical Inc$14K

What the payments were for

  • Food & beverage$52100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.1$52

How this compares

$52 in reported general payments places this provider in the 15th percentile of 74 nephrology providers in Utah.

See all nephrology providers in Utah

Medicare billing

Part B allowed, 2024
$162,570
Medicare patients
232
Services billed
1,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol12$8,413
Fluconazole19$378
Torsemide13$237
Omeprazole13$232
Amlodipine Besylate27$205

Paid to pharmacies, not to this prescriber.

Other nephrology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →